Search
Skip to Search Results- 3Prado, C. M.
- 1Angulo, P. Meza-Junco, J.
- 1Baracos, V. E.
- 1Beaumont, C.
- 1Esfandiari, N.
- 1Fogelman, D.
-
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
Download2014
Shroff, R., Katz, M. H., Overman, M. J., Khalil, M., Lieffers, J., Varadhachary, G. R., Fogelman, D., Javle, M. , Holmes, H., Prado, C. M.
BackgroundIGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.MethodsWe evaluated muscle mass at L3 in patients enrolled in a randomized phase...
-
2014
Prado, C. M., Ormsbee, M. J., Ilich, J. Z., Panton, L. , Siervo, M., Folsom, A., Purcell, S.
Osteopenia/osteoporosis, sarcopenia, and obesity are commonly observed in the process of aging, and recent evidence suggests a potential interconnection of these syndromes with common pathophysiology. The term osteosarcopenic obesity has been coined to describe the concurrent appearance of...
-
Sarcopenic obesity and myosteratosis are associated with higher mortality in patients with cirrhosis
Download2016
Beaumont, C., Angulo, P. Meza-Junco, J., Prado, C. M., Montano-Loza, A. J., Esfandiari, N., Sawyer, M. B., Ma, M., Baracos, V. E.
Background and aimsObesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous lossof skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletionis characterized by both a reduction in muscle...